Abstract:Background: Wnt activation promotes bone formation and prevents bone loss. The Wnt pathway antagonist sclerostin and additional anti-sclerostin antibodies were discovered as a result of the development of the monoclonal antibody romosozumab. These monoclonal antibodies greatly increase the risk of cardiac arrest. Three-dimensional quantitative structure-activity relationships (3D-QSAR) predicts biological activities of ligands based on their three-dimensional features by employing powerful chemometric investigations such as artificial neural networks (ANNs) and partial least squares (PLS). Objective: In this study, ligand-receptor interactions were investigated using 3D-QSAR Comparative molecular field analysis (CoMFA). Estimates of steric and electrostatic characteristics in CoMFA are made using Lennard-Jones and Coulomb potentials. Methods: To identify the conditions necessary for the activity of these molecules, fifty Food and Drug Administration (FDA)-approved medications were chosen for 3D-QSAR investigations and done by CoMFA. For QSAR analysis, there are numerous tools available. This study employed Open 3D-QSAR for analysis due to its simplicity of use and capacity to produce trustworthy results. Four tools were used for the analysis on this platform: Py-MolEdit, Py-ConfSearch, and Py-CoMFA. Results: Maps that were generated were used to determine the screen's r2 (Coefficient of Multiple Determinations) value and q2 (correlation coefficient). These numbers must be fewer than 1, suggesting a good, trustworthy model. Cross-validated (q2) 0.532 and conventional (r2) correlation values of 0.969 made the CoMFA model statistically significant. The model showed that hydroxamic acid inhibitors are significantly more sensitive to the steric field than the electrostatic field (70%) (30%). This hypothesis states that steric (43.1%), electrostatic (26.4%), and hydrophobic (20.3%) qualities were important in the design of sclerostin inhibitors. Conclusion: With 3D-QSAR and CoMFA, statistically meaningful models were constructed to predict ligand inhibitory effects. The test set demonstrated the model's robustness. This research may aid in the development of more effective sclerostin inhibitors that are synthesised using FDA-approved medications.

QSAR Modeling of Sphingomyelin Synthase 2 Inhibitors for Their Potential as Anti-Atherosclerotic Agents

Novel Dual Inhibitors of Secretory Phospholipase A2 and Sphingomyelin Synthase: Design, Synthesis and Evaluation

Discovery of the Selective Sphingomyelin Synthase 2 Inhibitors with the Novel Structure of Oxazolopyridine

Discovery, Synthesis and Anti-Atherosclerotic Activities of a Novel Selective Sphingomyelin Synthase 2 Inhibitor.

Discovery, Synthesis and Biological Evaluation of 2-(4-(n-phenethylsulfamoyl)phenoxy)acetamides (sapas) As Novel Sphingomyelin Synthase 1 Inhibitors

Identification of Small Molecule Sphingomyelin Synthase Inhibitors.

Discovery of 4-Benzyloxybenzo[d]isoxazole-3-amine Derivatives As Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors That Reduce Chronic Inflammation in Db/db Mice

Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase

The Sphingomyelin Synthase Family: Proteins, Diseases, and Inhibitors

Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis.

Research and study of 2-((4,6 dimethyl pyrimidine-2-yle) thio)-N-phenyl acetamide derivatives as inhibitors of sirtuin 2 protein for the treatment of cancer using QSAR, molecular docking and molecular dynamic simulation

Sphingomyelin Biosynthesis: Its Impact on Lipid Metabolism and Atherosclerosis

Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors

Prospects for the Use of Sialidase Inhibitors in Anti-atherosclerotic Therapy

QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition

Understanding Molecular Interactions Between Scavenger Receptor A and Its Natural Product Inhibitors Through Molecular Modeling Studies.

The Role of Sphingomyelin Synthase 2 (SMS2) in Platelet Activation and Its Clinical Significance

Integration of 3D-QSAR, Molecular Docking, and Machine Learning Techniques for Rational Design of Nicotinamide-Based SIRT2 Inhibitors

AI-based 3D-QSAR model of FDA-approved repurposed drugs for inhibiting sclerostin

Development of Innovative Antiatherosclerotic Peptides through the Combination of Molecular Modeling and a Dual (Biochemical‐Cellular) Screening System

Potential Therapeutic Targets for Atherosclerosis in Sphingolipid Metabolism